Amgen Inc SEC filings AMGN

Amgen Inc has 1,000 filings in SEC EDGAR's recent list, going back to May 22, 2018. Its latest annual report, Form ARS, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Mar 31, 2026 Dec 31, 2025
10-K Annual report Feb 13, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 2, 2025 Dec 31, 2024
10-K Annual report Feb 14, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 10, 2024 Dec 31, 2023
10-K Annual report Feb 14, 2024 Dec 31, 2023
ARS Annual report to shareholders Mar 30, 2023 Dec 31, 2022
10-K Annual report Feb 9, 2023 Dec 31, 2022
10-K Annual report Feb 16, 2022 Dec 31, 2021
10-K Annual report Feb 9, 2021 Dec 31, 2020
10-K/A Amended annual report Feb 13, 2020 Dec 31, 2019
10-K Annual report Feb 12, 2020 Dec 31, 2019
10-K Annual report Feb 13, 2019 Dec 31, 2018

Showing 13 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
AMGN (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Thousand Oaks, CA
SEC filer status
Large accelerated filer
SEC CIK
318154

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.